Conger Aaron, Sperry Beau P, Cheney Cole W, Kuo Keith, Petersen Russel, Randall Dustin, Salazar Fabio, Cunningham Shellie, Henrie A Michael, Bisson Erica, Kendall Richard, Teramoto Masaru, McCormick Zachary L
Division of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, UT.
Alabama College of Osteopathic Medicine, Dothan, AL.
Pain Med. 2020 Dec 25;21(12):3350-3359. doi: 10.1093/pm/pnaa305.
No study has evaluated the relationship between contrast dispersion patterns and outcomes after fluoroscopically guided cervical transforaminal epidural steroid injection (CTFESI).
Determine whether contrast dispersion patterns predict pain and functional outcomes after CTFESI.
Secondary analysis of data collected during two prospective studies of CTFESI for the treatment of refractory radicular pain. Contrast dispersion patterns visualized by true anteroposterior (AP) projections during CTFESIs were categorized by flow: 1) completely external to the lateral border of the neuroforamen (zone 1); 2) within the neuroforamen but without entry into the lateral epidural space (zone 2); and 3) with extension into the lateral epidural space (zone 3). At baseline and at 1 month post-CTFESI, neck pain, arm pain, and "dominant index pain" (the greater of arm or neck pain) were evaluated using a numeric rating scale (NRS); physical function was assessed using the Five-Item Version of the Neck Disability Index (NDI-5).
One-month post-CTFESI, neck pain, arm pain, and "dominant index pain" reductions of ≥50% were observed in 39.4% (95% confidence interval [CI], 28.2-51.8), 55.6% (95% CI, 43.0-67.5), and 44.1% (95% CI, 32.7-56.2) of participants, respectively. Regarding "dominant index pain," 72.7% (95% CI, 40.8-91.2), 39.4% (95% CI, 24.2-57.0), and 37.5% (95% CI, 20.5-58.2) of participants reported ≥50% pain reduction when zone 1, zone 2, and zone 3 contrast flow patterns were observed. Contrast dispersion zone was not significantly associated with subgroup differences in neck pain, arm pain, or NDI-5 scores (P>0.05).
Improvements in pain and function 1 month after treatment with CTFESI did not differ significantly based on the contrast dispersion pattern. Future study is needed to confirm or refute these findings in other procedural settings, in broader patient populations, and with longer-term outcome assessment.
尚无研究评估透视引导下颈椎椎间孔硬膜外类固醇注射(CTFESI)后造影剂弥散模式与治疗结果之间的关系。
确定CTFESI后造影剂弥散模式是否可预测疼痛和功能结果。
对两项关于CTFESI治疗难治性神经根性疼痛的前瞻性研究中收集的数据进行二次分析。CTFESI期间通过真正的前后位(AP)投影观察到的造影剂弥散模式按血流情况分类:1)完全位于神经孔外侧缘之外(1区);2)位于神经孔内但未进入外侧硬膜外间隙(2区);3)延伸至外侧硬膜外间隙(3区)。在基线和CTFESI后1个月,使用数字评分量表(NRS)评估颈部疼痛、手臂疼痛和“主要指标疼痛”(手臂或颈部疼痛中较重者);使用颈部功能障碍指数五项版本(NDI-5)评估身体功能。
CTFESI后1个月,分别有39.4%(95%置信区间[CI],28.2-51.8)、55.6%(95%CI,43.0-67.5)和44.1%(95%CI,32.7-56.2)的参与者颈部疼痛、手臂疼痛和“主要指标疼痛”减轻≥50%。关于“主要指标疼痛”,当观察到1区、2区和3区造影剂血流模式时,分别有72.7%(95%CI,40.8-91.2)、39.4%(95%CI,24.2-57.0)和37.5%(95%CI,20.5-58.2)的参与者报告疼痛减轻≥50%。造影剂弥散区与颈部疼痛、手臂疼痛或NDI-5评分的亚组差异无显著相关性(P>0.05)。
基于造影剂弥散模式,CTFESI治疗后1个月疼痛和功能的改善无显著差异。需要进一步研究在其他手术环境、更广泛的患者群体中以及进行长期结果评估来证实或反驳这些发现。